› Forums › General Melanoma Community › 2013 NIH report NRAS & IL-2
- This topic has 6 replies, 2 voices, and was last updated 12 years, 5 months ago by
JerryfromFauq.
- Post
-
- August 29, 2013 at 10:11 pm
2013 NIH report NRAS & IL-2
2013 NIH report NRAS & IL-2
Full article is interesting.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3241890/
"The main conclusion from this multi-center retrospective study patients with metastatic melanoma treated with HD IL-2 is that there was a statistically significant difference in the response rate (CR or PR) based on the tumor mutation status. Patients with NRAS mutations were more than twice as likely to respond to HD IL-2 than patients who were WT for NRAS (47% versus 19%, p=0.04). This is the first time that mutation status has been associated with response to HD IL-2 therapy for melanoma. We also observed a strong trend for a lower chance of response to HD IL2 among patients with elevated serum LDH, which also has not been reported previously."
- Replies
-
-
- August 29, 2013 at 10:22 pm
Thanks Jerry for simplifying these reports.For someone like myself I have to read them at least 3 times to try to make some sense on what they are saying.There are others that help interpert these results .My thanks go out to them also.Beat the Beast. Al
-
- August 29, 2013 at 10:22 pm
Thanks Jerry for simplifying these reports.For someone like myself I have to read them at least 3 times to try to make some sense on what they are saying.There are others that help interpert these results .My thanks go out to them also.Beat the Beast. Al
-
- August 29, 2013 at 10:22 pm
Thanks Jerry for simplifying these reports.For someone like myself I have to read them at least 3 times to try to make some sense on what they are saying.There are others that help interpert these results .My thanks go out to them also.Beat the Beast. Al
-
- August 30, 2013 at 3:52 am
Welcome.
-
- August 30, 2013 at 3:52 am
Welcome.
-
- August 30, 2013 at 3:52 am
Welcome.
-
- You must be logged in to reply to this topic.